kottke.org Follow In a late-stage trial, personalized mRNA vaccines for... In a late-stage trial, personalized mRNA vaccines for melanoma “reduced the risk of death or recurrence by 42 percent compared to standard treatment”. https://kottke.org/26/10/0049904-reduced-the-risk-of-death kottke.org
